Tag: PCSK9
Preclinical Study Shows Safety, Efficacy, and Durability of Lowering LDL-Cholesterol Levels...
Precision Biosciences announces preclinical study data that shows their proprietary genome editing platform, ARCUS, can safely cut down low density lipoprotein cholesterol levels in non human primates for three years following a single treatment. The study was conducted by the gene therapy program at the University of Pennsylvania and published in Molecular Therapy.
